Immutep to present clinical data from TACTI-003 Phase IIb trial

Immutep Limited announces details for an upcoming oral presentation at the European Society for Medical Oncology Virtual Plenary session on July 11, 2024, featuring new clinical data in patients with negative PD-L1 expression in the TACTI-003 Phase IIb trial, and a webcast to discuss these clinical results. ESMO Virtual Plenaries are monthly presentations of the latest, original scientific data, including “Phase II trials which demonstrate remarkable therapeutic benefit, scientific insight or progress in an area of unmet need”. The oral presentation will announce the substantially improved overall response rate, as advised 27 June 2024, and additional data in patients with first line head and neck squamous cell carcinoma who have negative PD-L1